|
1
|
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
|
Blood
|
2007
|
5.63
|
|
2
|
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
|
Blood
|
2006
|
4.35
|
|
3
|
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
|
Blood
|
2010
|
4.33
|
|
4
|
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
|
Clin Cancer Res
|
2005
|
4.00
|
|
5
|
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.
|
J Clin Oncol
|
2011
|
3.83
|
|
6
|
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
|
Blood
|
2006
|
3.48
|
|
7
|
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.
|
Cancer
|
2007
|
3.28
|
|
8
|
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
|
N Engl J Med
|
2015
|
3.25
|
|
9
|
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.
|
Blood
|
2005
|
3.24
|
|
10
|
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
|
Blood
|
2003
|
3.18
|
|
11
|
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
|
Cancer
|
2006
|
2.77
|
|
12
|
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
|
Blood
|
2003
|
2.75
|
|
13
|
Polycythemia vera is not initiated by JAK2V617F mutation.
|
Exp Hematol
|
2007
|
2.75
|
|
14
|
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
|
Cancer Res
|
2010
|
2.69
|
|
15
|
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
|
J Clin Oncol
|
2008
|
2.54
|
|
16
|
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
|
J Clin Oncol
|
2003
|
2.41
|
|
17
|
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.
|
Nat Rev Drug Discov
|
2011
|
2.38
|
|
18
|
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
|
Cancer
|
2004
|
2.31
|
|
19
|
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
|
Blood
|
2008
|
2.31
|
|
20
|
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.
|
Nature
|
2012
|
2.28
|
|
21
|
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
|
Clin Cancer Res
|
2006
|
2.23
|
|
22
|
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
|
Blood
|
2005
|
2.21
|
|
23
|
The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis.
|
Leuk Res
|
2009
|
2.19
|
|
24
|
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
|
Blood
|
2009
|
2.15
|
|
25
|
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
|
Blood
|
2003
|
2.06
|
|
26
|
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
|
J Clin Oncol
|
2010
|
2.02
|
|
27
|
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
|
Blood
|
2006
|
1.97
|
|
28
|
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).
|
Leuk Res
|
2007
|
1.97
|
|
29
|
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
|
Cancer
|
2007
|
1.95
|
|
30
|
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
|
J Clin Oncol
|
2005
|
1.93
|
|
31
|
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
|
Blood
|
2007
|
1.92
|
|
32
|
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
|
Cancer
|
2003
|
1.90
|
|
33
|
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
|
J Clin Oncol
|
2009
|
1.88
|
|
34
|
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
|
Blood
|
2003
|
1.87
|
|
35
|
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
|
Br J Haematol
|
2007
|
1.85
|
|
36
|
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
|
J Clin Oncol
|
2009
|
1.83
|
|
37
|
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
|
Blood
|
2009
|
1.82
|
|
38
|
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
|
Cancer
|
2008
|
1.80
|
|
39
|
Clofarabine combinations as acute myeloid leukemia salvage therapy.
|
Cancer
|
2008
|
1.77
|
|
40
|
Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
|
Cancer
|
2004
|
1.75
|
|
41
|
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
|
Blood
|
2006
|
1.73
|
|
42
|
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia.
|
Blood
|
2003
|
1.72
|
|
43
|
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
|
J Clin Oncol
|
2013
|
1.70
|
|
44
|
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
|
Clin Cancer Res
|
2004
|
1.68
|
|
45
|
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
|
Haematologica
|
2010
|
1.65
|
|
46
|
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.
|
Blood
|
2013
|
1.64
|
|
47
|
Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
|
Cancer
|
2010
|
1.64
|
|
48
|
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
|
J Clin Oncol
|
2009
|
1.64
|
|
49
|
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
|
Clin Cancer Res
|
2005
|
1.61
|
|
50
|
Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
|
Leuk Res
|
2013
|
1.61
|
|
51
|
Role of angiogenesis in chronic lymphocytic leukemia.
|
Cancer
|
2006
|
1.60
|
|
52
|
Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.
|
J Clin Oncol
|
2006
|
1.60
|
|
53
|
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
|
Clin Cancer Res
|
2013
|
1.59
|
|
54
|
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.
|
Blood
|
2011
|
1.58
|
|
55
|
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.
|
Blood
|
2013
|
1.57
|
|
56
|
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
|
Blood
|
2003
|
1.57
|
|
57
|
Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.
|
Blood
|
2010
|
1.50
|
|
58
|
Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis.
|
Leuk Lymphoma
|
2013
|
1.49
|
|
59
|
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
|
Blood
|
2004
|
1.49
|
|
60
|
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression.
|
Br J Haematol
|
2003
|
1.47
|
|
61
|
JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.
|
Blood
|
2013
|
1.46
|
|
62
|
Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.
|
Blood
|
2012
|
1.46
|
|
63
|
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.
|
Clin Cancer Res
|
2003
|
1.45
|
|
64
|
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
|
Blood
|
2008
|
1.44
|
|
65
|
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
|
Cancer
|
2003
|
1.42
|
|
66
|
Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis.
|
Leuk Lymphoma
|
2015
|
1.42
|
|
67
|
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
|
Blood
|
2004
|
1.41
|
|
68
|
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.
|
Leuk Res
|
2009
|
1.41
|
|
69
|
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
|
Cancer
|
2007
|
1.37
|
|
70
|
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
|
Blood
|
2012
|
1.34
|
|
71
|
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.
|
Blood
|
2013
|
1.33
|
|
72
|
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
|
Cancer
|
2009
|
1.29
|
|
73
|
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
|
Blood
|
2004
|
1.28
|
|
74
|
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.
|
Blood
|
2008
|
1.25
|
|
75
|
The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.
|
Blood
|
2008
|
1.25
|
|
76
|
Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies.
|
Cancer
|
2004
|
1.24
|
|
77
|
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
|
Blood
|
2005
|
1.23
|
|
78
|
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
|
Cancer
|
2014
|
1.22
|
|
79
|
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.
|
Blood
|
2013
|
1.19
|
|
80
|
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.
|
Blood
|
2007
|
1.18
|
|
81
|
Thalidomide therapy for myelofibrosis with myeloid metaplasia.
|
Cancer
|
2006
|
1.18
|
|
82
|
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.
|
Cancer
|
2007
|
1.16
|
|
83
|
Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.
|
J Mol Diagn
|
2008
|
1.16
|
|
84
|
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
|
Cancer Sci
|
2008
|
1.14
|
|
85
|
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome.
|
Br J Haematol
|
2004
|
1.14
|
|
86
|
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
|
Leuk Res
|
2003
|
1.13
|
|
87
|
Eradication of minimal residual disease in hairy cell leukemia.
|
Blood
|
2006
|
1.13
|
|
88
|
Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.
|
Cancer Res
|
2002
|
1.12
|
|
89
|
Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis.
|
Clin Lymphoma Myeloma Leuk
|
2010
|
1.12
|
|
90
|
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.
|
Blood
|
2009
|
1.11
|
|
91
|
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
|
Blood
|
2014
|
1.10
|
|
92
|
Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor.
|
Cancer Res
|
2011
|
1.10
|
|
93
|
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
|
Haematologica
|
2012
|
1.10
|
|
94
|
Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.
|
Am J Hematol
|
2013
|
1.09
|
|
95
|
Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells.
|
Mol Cancer Ther
|
2013
|
1.09
|
|
96
|
Investigational Janus kinase inhibitors.
|
Expert Opin Investig Drugs
|
2013
|
1.09
|
|
97
|
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
|
Clin Cancer Res
|
2004
|
1.08
|
|
98
|
Spinal epidural granulocytic sarcoma in non-leukemic patient.
|
Int J Hematol
|
2008
|
1.07
|
|
99
|
Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow.
|
Mod Pathol
|
2008
|
1.07
|
|
100
|
Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly.
|
Blood
|
2012
|
1.07
|
|
101
|
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
|
Blood
|
2005
|
1.06
|
|
102
|
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
|
Cancer
|
2003
|
1.06
|
|
103
|
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
|
Am J Hematol
|
2013
|
1.06
|
|
104
|
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
|
J Hematol Oncol
|
2013
|
1.05
|
|
105
|
Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.
|
Clin Cancer Res
|
2011
|
1.05
|
|
106
|
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor.
|
Cancer
|
2010
|
1.05
|
|
107
|
Inhibition of mammary carcinoma cell proliferation in vitro and tumor growth in vivo by bee venom.
|
Toxicon
|
2003
|
1.04
|
|
108
|
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
|
Blood
|
2006
|
1.04
|
|
109
|
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
|
Blood
|
2003
|
1.03
|
|
110
|
Novel approaches in the treatment of systemic mastocytosis.
|
Cancer
|
2006
|
1.03
|
|
111
|
Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
|
Cancer
|
2002
|
1.02
|
|
112
|
The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells.
|
Cancer Lett
|
2010
|
1.02
|
|
113
|
Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
|
J Clin Oncol
|
2009
|
1.02
|
|
114
|
Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
|
J Hematol Oncol
|
2012
|
1.02
|
|
115
|
JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?
|
Anticancer Agents Med Chem
|
2012
|
1.02
|
|
116
|
Outcome of patients with acute myelogenous leukemia after second salvage therapy.
|
Cancer
|
2005
|
1.01
|
|
117
|
International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.
|
Blood
|
2013
|
1.01
|
|
118
|
Activity of alemtuzumab in patients with CD52-positive acute leukemia.
|
Cancer
|
2006
|
1.01
|
|
119
|
Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies.
|
Antimicrob Agents Chemother
|
2006
|
1.01
|
|
120
|
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
|
Leuk Res
|
2005
|
1.00
|
|
121
|
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
|
Cancer
|
2010
|
1.00
|
|
122
|
Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.
|
Leuk Res
|
2008
|
1.00
|
|
123
|
Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study.
|
Leuk Res
|
2013
|
1.00
|
|
124
|
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
|
Leuk Res
|
2006
|
1.00
|
|
125
|
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.
|
Blood
|
2005
|
0.99
|
|
126
|
The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.99
|
|
127
|
The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia.
|
Clin Cancer Res
|
2012
|
0.99
|
|
128
|
A phase I clinical trial of darinaparsin in patients with refractory solid tumors.
|
Clin Cancer Res
|
2009
|
0.98
|
|
129
|
Mutations and promoter methylation status of NPM1 in myeloproliferative disorders.
|
Haematologica
|
2006
|
0.98
|
|
130
|
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
|
Cancer
|
2003
|
0.98
|
|
131
|
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.
|
Haematologica
|
2013
|
0.97
|
|
132
|
Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.
|
Blood
|
2011
|
0.97
|
|
133
|
JAK2 inhibitors: what's the true therapeutic potential?
|
Blood Rev
|
2010
|
0.97
|
|
134
|
New JAK2 inhibitors for myeloproliferative neoplasms.
|
Expert Opin Investig Drugs
|
2011
|
0.96
|
|
135
|
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
|
Cancer
|
2005
|
0.94
|
|
136
|
Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
|
Cancer
|
2011
|
0.94
|
|
137
|
The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
|
Haematologica
|
2003
|
0.94
|
|
138
|
Significance of cytogenetic abnormalities in patients with polycythemia vera.
|
Leuk Lymphoma
|
2013
|
0.93
|
|
139
|
Ruxolitinib for the treatment of myelofibrosis: its clinical potential.
|
Ther Clin Risk Manag
|
2012
|
0.93
|
|
140
|
Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
|
Leuk Res
|
2006
|
0.92
|
|
141
|
Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML.
|
Blood
|
2003
|
0.92
|
|
142
|
Pregnancy in a patient with hypereosinophilic syndrome.
|
Leuk Res
|
2008
|
0.92
|
|
143
|
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
|
Cancer
|
2007
|
0.92
|
|
144
|
Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis.
|
Cancer
|
2011
|
0.91
|
|
145
|
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.
|
Cancer
|
2004
|
0.91
|
|
146
|
Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples.
|
Genet Test Mol Biomarkers
|
2013
|
0.91
|
|
147
|
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.
|
Clin Cancer Res
|
2005
|
0.91
|
|
148
|
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
|
Invest New Drugs
|
2008
|
0.91
|
|
149
|
How we diagnose and treat WHO-defined systemic mastocytosis in adults.
|
Haematologica
|
2008
|
0.91
|
|
150
|
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
|
Clin Cancer Res
|
2005
|
0.90
|
|
151
|
Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.
|
Support Care Cancer
|
2009
|
0.90
|
|
152
|
Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
|
Cancer
|
2006
|
0.90
|
|
153
|
Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.90
|
|
154
|
Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
|
Leuk Lymphoma
|
2014
|
0.89
|
|
155
|
In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
|
Cancer
|
2002
|
0.88
|
|
156
|
A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia.
|
Cancer
|
2007
|
0.88
|
|
157
|
Advances in the therapy of chronic idiopathic myelofibrosis.
|
Oncologist
|
2006
|
0.88
|
|
158
|
Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera.
|
Clin Immunol
|
2006
|
0.87
|
|
159
|
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
|
Cancer
|
2003
|
0.87
|
|
160
|
An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions.
|
J Immunol
|
2006
|
0.87
|
|
161
|
Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.
|
Clin Cancer Res
|
2008
|
0.87
|
|
162
|
Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations.
|
Cancer Genet Cytogenet
|
2010
|
0.87
|
|
163
|
Imatinib effect on growth and signal transduction in polycythemia vera.
|
Exp Hematol
|
2007
|
0.87
|
|
164
|
Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation.
|
Biol Blood Marrow Transplant
|
2010
|
0.87
|
|
165
|
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
|
Am J Hematol
|
2004
|
0.87
|
|
166
|
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
|
Leuk Res
|
2005
|
0.86
|
|
167
|
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.
|
Cancer
|
2005
|
0.86
|
|
168
|
Primary autoimmune myelofibrosis in a 36-year-old patient presenting with isolated extreme anemia.
|
Leuk Res
|
2009
|
0.86
|
|
169
|
Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis.
|
Leuk Res
|
2012
|
0.85
|
|
170
|
Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.85
|
|
171
|
Therapy with JAK2 inhibitors for myeloproliferative neoplasms.
|
Hematol Oncol Clin North Am
|
2012
|
0.85
|
|
172
|
Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation.
|
Leuk Lymphoma
|
2013
|
0.85
|
|
173
|
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.
|
Cancer
|
2011
|
0.85
|
|
174
|
Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.
|
Expert Rev Anticancer Ther
|
2009
|
0.84
|
|
175
|
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
|
Cancer
|
2007
|
0.84
|
|
176
|
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
|
Blood
|
2009
|
0.84
|
|
177
|
Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?
|
Br J Haematol
|
2012
|
0.84
|
|
178
|
Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies.
|
Leuk Res
|
2013
|
0.83
|
|
179
|
Chromosome 5q deletion is extremely rare in patients with myelofibrosis.
|
Leuk Res
|
2013
|
0.83
|
|
180
|
Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity.
|
Leuk Lymphoma
|
2012
|
0.83
|
|
181
|
The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.
|
Ann Hematol
|
2013
|
0.83
|
|
182
|
Janus-activated kinase 2 inhibitors: a new era of targeted therapies providing significant clinical benefit for Philadelphia chromosome-negative myeloproliferative neoplasms.
|
J Clin Oncol
|
2011
|
0.83
|
|
183
|
Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.83
|
|
184
|
Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.
|
Invest New Drugs
|
2010
|
0.83
|
|
185
|
Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.82
|
|
186
|
Experimental therapeutics for patients with myeloproliferative neoplasias.
|
Cancer
|
2010
|
0.82
|
|
187
|
Practical management of patients with myelofibrosis receiving ruxolitinib.
|
Expert Rev Hematol
|
2013
|
0.82
|
|
188
|
Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse.
|
Br J Haematol
|
2006
|
0.82
|
|
189
|
Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders.
|
Semin Thromb Hemost
|
2006
|
0.81
|
|
190
|
In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines.
|
Cancer Chemother Pharmacol
|
2003
|
0.81
|
|
191
|
Comorbidities predict worse prognosis in patients with primary myelofibrosis.
|
Cancer
|
2014
|
0.81
|
|
192
|
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.
|
J Clin Oncol
|
2009
|
0.81
|
|
193
|
Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia.
|
Cancer Chemother Pharmacol
|
2002
|
0.81
|
|
194
|
New approaches in the treatment of myelofibrosis.
|
Cancer
|
2005
|
0.81
|
|
195
|
A potential role of ruxolitinib in leukemia.
|
Expert Opin Investig Drugs
|
2011
|
0.81
|
|
196
|
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
|
Leuk Res
|
2003
|
0.81
|
|
197
|
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.
|
Leuk Res
|
2006
|
0.81
|
|
198
|
TP53 mutation is rare in primary myelofibrosis.
|
Leuk Lymphoma
|
2012
|
0.80
|
|
199
|
Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis.
|
Leuk Lymphoma
|
2010
|
0.80
|
|
200
|
Advances in the management of myelofibrosis.
|
Cancer Control
|
2012
|
0.80
|
|
201
|
Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase.
|
J Clin Oncol
|
2011
|
0.79
|
|
202
|
Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome.
|
Cancer
|
2010
|
0.79
|
|
203
|
Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.
|
Future Oncol
|
2011
|
0.79
|
|
204
|
Primary autoimmune myelofibrosis (MF) with high-grade peripheral T-cell lymphoma (PTCL) NOS.
|
Eur J Haematol
|
2013
|
0.79
|
|
205
|
Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001.
|
Int J Hematol
|
2009
|
0.79
|
|
206
|
Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis.
|
Leuk Lymphoma
|
2013
|
0.79
|
|
207
|
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis.
|
Br J Haematol
|
2014
|
0.79
|
|
208
|
Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2016
|
0.78
|
|
209
|
MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells.
|
Invest New Drugs
|
2009
|
0.78
|
|
210
|
T-cell prolymphocytic leukemia: a single-institution experience.
|
Clin Lymphoma Myeloma
|
2005
|
0.78
|
|
211
|
Metastatic splenic angiosarcoma presenting with thrombocytopenia and bone marrow fibrosis mimicking idiopathic thrombocytopenic purpura and primary myelofibrosis: a diagnostic challenge.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.78
|
|
212
|
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
|
Cancer
|
2006
|
0.78
|
|
213
|
Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation.
|
Int J Hematol
|
2009
|
0.78
|
|
214
|
Chemical and clinical development of darinaparsin, a novel organic arsenic derivative.
|
Anticancer Agents Med Chem
|
2008
|
0.78
|
|
215
|
Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement.
|
Blood
|
2013
|
0.78
|
|
216
|
Treatment of myelofibrosis in younger patients: to transplant or not?
|
Am J Hematol
|
2009
|
0.78
|
|
217
|
Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial.
|
Haematologica
|
2013
|
0.78
|
|
218
|
Emerging drugs for myelofibrosis.
|
Expert Opin Emerg Drugs
|
2012
|
0.77
|
|
219
|
Treatment of aggressive systemic mastocytosis with daclizumab.
|
Leuk Lymphoma
|
2010
|
0.77
|
|
220
|
Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
|
Future Oncol
|
2015
|
0.77
|
|
221
|
JAK2 inhibitors: are they the solution?
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.77
|
|
222
|
Efficacy of ruxolitinib for myelofibrosis.
|
Expert Opin Pharmacother
|
2014
|
0.77
|
|
223
|
Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells.
|
Cancer Sci
|
2006
|
0.77
|
|
224
|
Breakthroughs in myeloproliferative neoplasms.
|
Hematology
|
2012
|
0.77
|
|
225
|
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986.
|
Cancer
|
2005
|
0.77
|
|
226
|
What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?
|
Curr Opin Hematol
|
2013
|
0.77
|
|
227
|
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation.
|
Br J Haematol
|
2004
|
0.76
|
|
228
|
Treatment of systemic mastocytosis with denileukin diftitox.
|
Am J Hematol
|
2007
|
0.76
|
|
229
|
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
|
Cancer Chemother Pharmacol
|
2003
|
0.76
|
|
230
|
Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition.
|
Expert Rev Hematol
|
2012
|
0.76
|
|
231
|
Primary myelofibrosis with concurrent precursor T-cell lymphoblastic lymphoma of the spleen in a 26-year-old patient.
|
Leuk Res
|
2009
|
0.76
|
|
232
|
Arsenic derivatives as therapeutic agents for hematologic malignancies.
|
Leuk Res
|
2004
|
0.76
|
|
233
|
An unusual case of aggressive systemic mastocytosis with associated refractory plasma cell myeloma.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.76
|
|
234
|
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
|
Cancer Chemother Pharmacol
|
2003
|
0.76
|
|
235
|
Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.76
|
|
236
|
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
|
Cancer
|
2003
|
0.76
|
|
237
|
Mycotic pulmonary artery aneurysm due to Aspergillus infection in a patient with leukemia: case report and review of the literature.
|
Leuk Res
|
2010
|
0.76
|
|
238
|
Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome.
|
Leuk Res
|
2013
|
0.75
|
|
239
|
Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosis.
|
Leuk Lymphoma
|
2014
|
0.75
|
|
240
|
Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406.
|
Cancer Sci
|
2007
|
0.75
|
|
241
|
The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells.
|
Anticancer Res
|
2012
|
0.75
|
|
242
|
Long non-coding RNAs in primary myelofibrosis: the dark matter in hematopoietic progenitor cells?
|
Leuk Lymphoma
|
2015
|
0.75
|
|
243
|
Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy.
|
Haematologica
|
2011
|
0.75
|
|
244
|
Is there still a role for interferon-alpha for newly diagnosed chronic myeloid leukemia in chronic phase?
|
Leuk Lymphoma
|
2007
|
0.75
|
|
245
|
Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
|
Clin Lymphoma Myeloma Leuk
|
2010
|
0.75
|
|
246
|
Ruxolitinib for the treatment of patients with polycythemia vera.
|
Expert Rev Hematol
|
2015
|
0.75
|
|
247
|
Paroxysmal nocturnal hemoglobinuria is not a cause of anemia in patients with myelofibrosis.
|
Leuk Lymphoma
|
2014
|
0.75
|
|
248
|
Competing cell clones in myeloproliferative neoplasm.
|
Blood
|
2010
|
0.75
|
|
249
|
Retrospect of hematologic malignancies 2010.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.75
|
|
250
|
Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.
|
Leuk Res
|
2003
|
0.75
|
|
251
|
Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia.
|
Curr Hematol Malig Rep
|
2007
|
0.75
|
|
252
|
JAK2 inhibitors: A reality? A hope?
|
Clin Lymphoma Myeloma
|
2009
|
0.75
|
|
253
|
Thrombosis of the corpora cavernosa complicating lenalidomide therapy of myelofibrosis.
|
Leuk Res
|
2007
|
0.75
|
|
254
|
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
|
Cancer
|
2003
|
0.75
|
|
255
|
Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease.
|
Cancer J
|
2007
|
0.75
|
|
256
|
Granulocytic sarcoma with massive scalp involvement.
|
Am J Hematol
|
2008
|
0.75
|
|
257
|
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
|
Leuk Res
|
2003
|
0.75
|
|
258
|
Flow cytometric immunophenotypic analysis of systemic mastocytosis involving bone marrow.
|
Arch Pathol Lab Med
|
2014
|
0.75
|
|
259
|
Aberrant myeloid maturation identified by flow cytometry in primary myelofibrosis.
|
Am J Clin Pathol
|
2010
|
0.75
|
|
260
|
A Rare Case of Primary Myelofibrosis in a 14-Year-Old Patient With Congenital Asplenia.
|
J Pediatr Hematol Oncol
|
2016
|
0.75
|
|
261
|
Experience with oral interferon-alpha in patients with essential thrombocythemia and polycythemia vera.
|
Am J Hematol
|
2007
|
0.75
|
|
262
|
'Janus kinase-ing' up the treatment of primary myelofibrosis: building better combination strategies.
|
Curr Opin Hematol
|
2017
|
0.75
|